Related Experiment Video
Updated: Sep 14, 2025
Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
Published on: February 16, 2022
Comparative assessment of a multiplex micro-chip immunoassay, VaxArray, and meso scale discovery assay for
Ashvi Sanjay Jain1, Thorsten Verch2, Gowrisankar Rajam2
1Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
Immunoassays for serology have advanced from radio-immunoassays to multiplexed micro-array-based technologies over the past years. Comparative studies can assist users in selecting an assay platform based on its applicability and performance characteristics. This study compared a 9-plex commercial VaxArray Coronavirus SeroAssay (InDevR) and a 10-plex semi-custom Coronavirus SeroAssay (MSD) with a panel of human serum samples. The MSD assay showed superior dynamic range and sensitivity across all coronavirus serotypes, while both assays met accuracy (100 ± 20 %) and precision (%CV < 25 %) criteria. Although both platforms were concordant for anti-SARS-CoV2 IgG measurements, the clinical sensitivity and specificity of the MSD assay were marginally higher than those of VaxArray. Despite VaxArray's shorter total assay time and higher potential for multiplexing and re-readability, it requires improvements in dynamic range, sensitivity, specificity, and automation capabilities for regulated use.
Immunoassays for serology have advanced from radio-immunoassays to multiplexed micro-array-based technologies over the past years. Comparative studies can assist users in selecting an assay platform based on its applicability and performance characteristics. This study compared a 9-plex commercial VaxArray Coronavirus SeroAssay (InDevR) and a 10-plex semi-custom Coronavirus SeroAssay (MSD) with a panel of human serum samples. The MSD assay showed superior dynamic range and sensitivity across all coronavirus serotypes, while both assays met accuracy (100 ± 20 %) and precision (%CV < 25 %) criteria. Although both platforms were concordant for anti-SARS-CoV2 IgG measurements, the clinical sensitivity and specificity of the MSD assay were marginally higher than those of VaxArray. Despite VaxArray's shorter total assay time and higher potential for multiplexing and re-readability, it requires improvements in dynamic range, sensitivity, specificity, and automation capabilities for regulated use.
More Related Videos
07:08A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System
Published on: April 6, 2021
05:25Author Spotlight: Expanding the Scope of Multiplex Immunoassays for Lyme Borreliosis Diagnostics and Pathogen Research
Published on: July 14, 2023